Payment overview · 2025
General Payments
$1,669.03
84 reported records · 20 companies
Healthcare provider profile · identity verified
Michael Anthony Stephens, MD
Allopathic & Osteopathic Physicians|Family Medicine · ORANGE PARK, FL · NPI 1801888607
Verified facts
What the public records show
CMS Open Payments records show Michael Anthony Stephens, MD received $1,669.03 in general payments during 2025 across 84 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Prolia, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 451 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $208.80 | 12.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $205.76 | 12.3% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $194.35 | 11.6% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $175.35 | 10.5% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $116.66 | 7.0% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $111.73 | 6.7% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $95.46 | 5.7% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $78.88 | 4.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $76.36 | 4.6% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $61.10 | 3.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $60.45 | 3.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $54.32 | 3.2% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $46.97 | 2.8% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $40.70 | 2.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $34.94 | 2.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.33 | 2.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.94 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.78 | 1.2% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $14.42 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.73 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,669.03 | 84 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $175.35 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $173.35 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $158.34 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $140.53 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $139.33 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $106.78 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $103.32 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $95.46 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $87.57 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $85.45 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $83.65 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $82.57 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $76.36 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $74.03 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $61.10 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.90 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $54.32 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $53.50 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.83 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.83 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $46.97 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $41.25 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $40.70 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.97 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $34.94 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.33 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 451 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 65 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 76 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 144 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
122 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
144 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
451 | 65 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1215 | 235 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1069 | 197 |
| Omeprazole | Omeprazole | 905 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 854 | 190 |
| Losartan Potassium | Losartan Potassium | 743 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 661 | 153 |
| Lisinopril | Lisinopril | 645 | 138 |
| Furosemide | Furosemide | 503 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 503 | 102 |
| Gabapentin | Gabapentin | 477 | 87 |
| Sertraline Hcl | Sertraline Hcl | 469 | 86 |
| Simvastatin | Simvastatin | 457 | 88 |
| Eliquis | Apixaban | 451 | 65 |
| Trazodone Hcl | Trazodone Hcl | 416 | 107 |
| Alprazolam | Alprazolam | 399 | 102 |
| Metoprolol Tartrate | Metoprolol Tartrate | 392 | 72 |
| Meloxicam | Meloxicam | 391 | 106 |
| Metoprolol Succinate | Metoprolol Succinate | 368 | 75 |
| Tramadol Hcl | Tramadol Hcl | 361 | 112 |
| Metformin Hcl | Metformin Hcl | 330 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 314 | 69 |
| Spironolactone | Spironolactone | 292 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 279 | 72 |
| Potassium Chloride | Potassium Chloride | 266 | 44 |
| Famotidine | Famotidine | 265 | 45 |
| Montelukast Sodium | Montelukast Sodium | 257 | 44 |
| Donepezil Hcl | Donepezil Hcl | 243 | 31 |
| Glimepiride | Glimepiride | 231 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 222 | 44 |
| Allopurinol | Allopurinol | 218 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 214 | 32 |
| Carvedilol | Carvedilol | 210 | 45 |
| Azelastine Hcl | Azelastine Hcl | 204 | 75 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 202 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 200 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 194 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 177 | 60 |
| Pregabalin | Pregabalin | 174 | 39 |
| Torsemide | Torsemide | 161 | 26 |
| Ezetimibe | Ezetimibe | 157 | 29 |
| Azithromycin | Azithromycin | 152 | 135 |
| Atenolol | Atenolol | 150 | 25 |
| Myrbetriq | Mirabegron | 145 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 145 | 34 |
| Ozempic | Semaglutide | 144 | 22 |
| Finasteride | Finasteride | 140 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 139 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 31 |
| Lorazepam | Lorazepam | 130 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 122 | 21 |
| Januvia | Sitagliptin Phosphate | 120 | 20 |
| Alendronate Sodium | Alendronate Sodium | 114 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 111 | 77 |
| Memantine Hcl | Memantine Hcl | 109 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 102 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 96 | 71 |
| Warfarin Sodium | Warfarin Sodium | 96 | 14 |
| Nifedipine Er | Nifedipine | 91 | 14 |
| Baclofen | Baclofen | 88 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 16 |
| Lidocaine | Lidocaine | 85 | 18 |
| Buspirone Hcl | Buspirone Hcl | 84 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 84 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 82 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 82 | 15 |
| Synthroid | Levothyroxine Sodium | 82 | 17 |
| Bupropion Xl | Bupropion Hcl | 80 | 16 |
| Glipizide | Glipizide | 79 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 78 | 12 |
| Xarelto | Rivaroxaban | 77 | 13 |
| Jardiance | Empagliflozin | 76 | 16 |
| Celecoxib | Celecoxib | 74 | 19 |
| Fenofibrate | Fenofibrate | 74 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 72 | 13 |
| Valsartan | Valsartan | 72 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 12 |
| Oxcarbazepine | Oxcarbazepine | 71 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 70 | 14 |
| Latanoprost | Latanoprost | 68 | 11 |
| Prednisone | Prednisone | 68 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 26 |
| Farxiga | Dapagliflozin Propanediol | 65 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 62 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 48 |
| Meclizine Hcl | Meclizine Hcl | 61 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 61 | 21 |
| Clonazepam | Clonazepam | 59 | 19 |
| Primidone | Primidone | 59 | 12 |
| Chlorthalidone | Chlorthalidone | 57 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 57 | suppressed |
| Temazepam | Temazepam | 55 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 13 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 53 | suppressed |
| Mirtazapine | Mirtazapine | 53 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | 16 |
| Valacyclovir | Valacyclovir Hcl | 52 | 17 |
| Entresto | Sacubitril/Valsartan | 51 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 13 |
| Telmisartan | Telmisartan | 50 | 13 |
| Levofloxacin | Levofloxacin | 49 | 36 |
| Lovastatin | Lovastatin | 48 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 45 | suppressed |
| Topiramate | Topiramate | 45 | suppressed |
| Digoxin | Digoxin | 44 | suppressed |
| Ibuprofen | Ibuprofen | 44 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 43 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 42 | suppressed |
| Mupirocin | Mupirocin | 42 | 31 |
| Rybelsus | Semaglutide | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 12 |
| Ketoconazole | Ketoconazole | 39 | 16 |
| Nystatin | Nystatin | 39 | 22 |
| Risperidone | Risperidone | 38 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 37 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 13 |
| Estradiol | Estradiol | 36 | 13 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Movantik | Naloxegol Oxalate | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 13 |
| Megestrol Acetate | Megestrol Acetate | 32 | 13 |
| Ammonium Lactate | Ammonium Lactate | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 20 |
| Cephalexin | Cephalexin | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Nystop | Nystatin | 29 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 13 |
| Tradjenta | Linagliptin | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Cholestyramine Light | Cholestyramine | 26 | suppressed |
| Gemtesa | Vibegron | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 11 |
| Bumetanide | Bumetanide | 25 | suppressed |
| Calcitriol | Calcitriol | 25 | suppressed |
| Diazepam | Diazepam | 25 | 13 |
| Indomethacin | Indomethacin | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 17 |
| Mometasone Furoate | Mometasone Furoate | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 12 |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Fluocinonide | Fluocinonide | 17 | suppressed |
| Hydroxyurea | Hydroxyurea | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Loteprednol Etabonate | Loteprednol Etabonate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 14 | suppressed |
| Bimatoprost | Bimatoprost | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 13 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Travoprost | Travoprost | 12 | suppressed |
| Victoza 2-Pak | Liraglutide | 12 | suppressed |
| Aciphex | Rabeprazole Sodium | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Theo-24 | Theophylline Anhydrous | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,669.03 · 84 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, Heplisav-B, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy, XYOSTED, ZAVZPRET, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error